Conversion Surgery Following Combination Treatment With Immune Checkpoint Inhibitors and Chemotherapy for Initially Unresectable Gastric Cancer
World Journal of Surgery · 2026-06 · 50 (6) · 1631-1638
DOI: 10.1002/wjs.70372 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Surgery, online erschienen am 16.04.2026. Verfasst von Masaaki Nishi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Tokushima Graduate School, Tokushima, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Gastrectomy, Immune Checkpoint Inhibitors, Stomach Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aim
Conversion surgery (CS) for unresectable advanced gastric cancer (GC; clinical stage IVb) has increased in recent years owing to advances in drug therapy. However, little is known about CS following combination treatment with immune checkpoint inhibitors (ICIs) and chemotherapy.
Methods
We conducted a retrospective cohort study of patients initially unresectable metastatic GC. We treated 36 patients with initially unresectable metastatic GC. Thirty‐four patients received combination treatment with ICIs and chemotherapy, 11 of whom underwent CS. We evaluated their short‐term and long‐term surgical outcomes.
Results
Among patients who underwent CS, six were male and five female, and the median (interquartile range) age was 71 (47–75) years. All patients started first‐line therapy with S‐1 plus oxaliplatin combined with nivolumab, and two patients underwent surgery after second‐line treatment with ramucirumab and nanoparticle albumin‐bound paclitaxel. There were four open, two laparoscopic, and five robotic surgeries. The median operative time was 348 (321–354) minutes, blood loss was 16 (10–30) mL, and number of retrieved lymph nodes was 38 (27–44); there were no cases of conversion to laparotomy. R0 resection was achieved in all patients. And postoperative pathology was complete response; three patients, ypStage I; four patients, II; three patient, III; zero patient IV; one patient. ICI and chemotherapy efficacy was Grade 1 in four patients, Grade 2 in two patients, and Grade 3 in five patients. Overall 2‐year survival was 90.0% for those who underwent CS.
Conclusion
CS following combination treatment with ICI and chemotherapy may be promising for initially unresectable metastatic GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of Tokushima Graduate School, Tokushima, Japan.
Zitieren
APA
Nishi, M., Wada, Y., Takasu, C., Tokunaga, T., Nakao, T., Kashihara, H., Yoshimoto, T., & Shimada, M. (2026). Conversion Surgery Following Combination Treatment With Immune Checkpoint Inhibitors and Chemotherapy for Initially Unresectable Gastric Cancer. World Journal of Surgery, 50(6), 1631-1638. https://doi.org/10.1002/wjs.70372
Vancouver
Nishi M, Wada Y, Takasu C, Tokunaga T, Nakao T, Kashihara H, et al. Conversion Surgery Following Combination Treatment With Immune Checkpoint Inhibitors and Chemotherapy for Initially Unresectable Gastric Cancer. World Journal of Surgery. 2026;50(6):1631-1638. doi:10.1002/wjs.70372
BibTeX
@article{Nishi2026,
author = {Nishi, Masaaki and Wada, Yuma and Takasu, Chie and Tokunaga, Takuya and Nakao, Toshihiro and Kashihara, Hideya and Yoshimoto, Toshiaki and Shimada, Mitsuo},
title = {Conversion Surgery Following Combination Treatment With Immune Checkpoint Inhibitors and Chemotherapy for Initially Unresectable Gastric Cancer},
journal = {World Journal of Surgery},
year = {2026},
volume = {50},
number = {6},
pages = {1631--1638},
doi = {10.1002/wjs.70372}
}
EUVIMED